Aurora Kinase A Regulates M1 Macrophage Polarization and Plays a Role in Experimental Autoimmune Encephalomyelitis

Inflammation

Volumn 38, Issue 2, 2015, Pages 800-811

  Ding, Lixia ^a   Gu, Haijuan ^a   Gao, Xiaoming ^a   Xiong, Sidong ^a   Zheng, Biao ^b,c  

^a SOOCHOW UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aurora kinase; autoimmune diseases; inflammation; M1 macrophage polarization

Indexed keywords

AURORA A KINASE; CARBON TETRACHLORIDE; CD163 ANTIGEN; CD36 ANTIGEN; CHEMOKINE RECEPTOR CCR7; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; REGULATOR PROTEIN; SMALL INTERFERING RNA; TOZASERTIB; TUMOR NECROSIS FACTOR ALPHA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMYELINATION; DISEASE COURSE; DOWN REGULATION; ENZYME INHIBITION; EX VIVO STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE EXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIMB WEAKNESS; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MACROPHAGE POLARIZATION; MOUSE; NONHUMAN; PARALYSIS; PARAPLEGIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA EXTRACTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL POLARITY; DOSE RESPONSE; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYMOLOGY; HUMAN; MACROPHAGE; PHYSIOLOGY;

ANIMALS; AURORA KINASE A; CELL POLARITY; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; PIPERAZINES; PROTEIN KINASE INHIBITORS;

EID: 84923848816     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9990-2     Document Type: Article

References (33)

1. Martinez, F.O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annual Review of Immunology 27: 451–483.
2. Gordon, S., and F.O. Martinez. 2010. Alternative activation of macrophages: mechanism and functions. Immunity 32: 593–604.
3. Mantovani, A., A. Sica, and M. Locati. 2005. Macrophage polarization comes of age. Immunity 23: 344–346.
4. Stein, M., S. Keshav, N. Harris, and S. Gordon. 1992. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. Journal of Experimental Medicine 176: 287–292.
5. Martinez, F.O., S. Gordon, M. Locati, and A. Mantovani. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. Journal of Immunology 177: 7303–7311.
6. Biswas, S.K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology 11: 889–896.
7. Shimada, K. 2009. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circulation Journal 73: 994–1001.
8. Adamson, S., and N. Leitinger. 2011. Phenotypic modulation of macrophages in response to plaque lipids. Current Opinion in Lipidology 22: 335–342.
9. Gosselin, L.E., and K.M. McCormick. 2004. Targeting the immune system to improve ventilatory function in muscular dystrophy. Medicine and Science in Sports and Exercise 36: 44–51.
10. Mikita, J., N. Dubourdieu-Cassagno, M. S. Deloire, A. Vekris, M. Biran, G. Raffard, B. Brochet, M. H. Canron, J. M. Franconi, C. Boiziau, and K. G. Petry. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler 17:2–15.
11. Weber, M.S., T. Prod'homme, S. Youssef, S.E. Dunn, C.D. Rundle, L. Lee, J.C. Patarroyo, O. Stuve, R.A. Sobel, L. Steinman, and S.S. Zamvil. 2007. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Medicine 13: 935–943.
12. Dar, A.A., L.W. Goff, S. Majid, J. Berlin, and W. El-Rifai. 2010. Aurora kinase inhibitors—rising stars in cancer therapeutics? Molecular Cancer Therapeutics 9: 268–278.
13. Carmena, M., S. Ruchaud, and W.C. Earnshaw. 2009. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Current Opinion in Cell Biology 21: 796–805.
14. Macarulla, T., F.J. Ramos, and J. Tabernero. 2008. Aurora kinase family: a new target for anticancer drug. Recent Patents on Anti-Cancer Drug Discovery 3: 114–122.
15. Mountzios, G., E. Terpos, and M.A. Dimopoulos. 2008. Aurora kinases as targets for cancer therapy. Cancer Treatment Reviews 34: 175–182.
16. Katsha, A., M. Soutto, V. Sehdev, D. Peng, M. K. Washington, M. B. Piazuelo, M. N. Tantawy, H. C. Manning, P. Lu, Y. Shyr, J. Ecsedy, A. Belkhiri, and W. El-Rifai. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 145:1312–1322 e1311-1318.
17. Glant, T. T., T. Besenyei, A. Kadar, J. Kurko, B. Tryniszewska, J. Gal, G. Soos, Z. Szekanecz, G. Hoffmann, J. A. Block, R. S. Katz, K. Mikecz, and T. A. Rauch. Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models. Arthritis Rheum 65:1725–1735.
18. Walter, A.O., W. Seghezzi, W. Korver, J. Sheung, and E. Lees. 2000. The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 19: 4906–4916.
19. Garuti, L., M. Roberti, and G. Bottegoni. 2009. Small molecule aurora kinases inhibitors. Current Medicinal Chemistry 16: 1949–1963.
20. Cheung, C.H., M.S. Coumar, J.Y. Chang, and H.P. Hsieh. 2011. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009–10). Expert Opinion on Therapeutic Patents 21: 857–884.
21. Kollareddy, M., D. Zheleva, P. Dzubak, P.S. Brahmkshatriya, M. Lepsik, and M. Hajduch. 2012. Aurora kinase inhibitors: progress towards the clinic. Investigational New Drugs 30: 2411–2432.
22. Wang, Z., J. Hong, W. Sun, G. Xu, N. Li, X. Chen, A. Liu, L. Xu, B. Sun, and J.Z. Zhang. 2006. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. Journal of Clinical Investigation 116: 2434–2441.
23. Okuda, Y., S. Sakoda, H. Fujimura, and T. Yanagihara. 2000. The effect of apoptosis inhibitors on experimental autoimmune encephalomyelitis: apoptosis as a regulatory factor. Biochemical and Biophysical Research Communications 267: 826–830.
24. Zappia, E., S. Casazza, E. Pedemonte, F. Benvenuto, I. Bonanni, E. Gerdoni, D. Giunti, A. Ceravolo, F. Cazzanti, F. Frassoni, G. Mancardi, and A. Uccelli. 2005. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755–1761.
25. Davis, M.J., T.M. Tsang, Y. Qiu, J.K. Dayrit, J.B. Freij, G.B. Huffnagle, and M.A. Olszewski. 2013. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio 4: e00264–00213.
26. Krausgruber, T., K. Blazek, T. Smallie, S. Alzabin, H. Lockstone, N. Sahgal, T. Hussell, M. Feldmann, and I.A. Udalova. 2011. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nature Immunology 12: 231–238.
27. Harrington, E.A., D. Bebbington, J. Moore, R.K. Rasmussen, A.O. Ajose-Adeogun, T. Nakayama, J.A. Graham, C. Demur, T. Hercend, A. Diu-Hercend, M. Su, J.M. Golec, and K.M. Miller. 2004. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Medicine 10: 262–267.
28. Sehdev, V., D. Peng, M. Soutto, M. K. Washington, F. Revetta, J. Ecsedy, A. Zaika, T. T. Rau, R. Schneider-Stock, A. Belkhiri, and W. El-Rifai. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 11:763–774.
29. Karin, M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431–436.
30. Dar, A.A., A. Zaika, M.B. Piazuelo, P. Correa, T. Koyama, A. Belkhiri, K. Washington, A. Castells, M. Pera, and W. El-Rifai. 2008. Frequent overexpression of Aurora kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 112: 1688–1698.
31. Madrid, L.V., M.W. Mayo, J.Y. Reuther, and A.S. Baldwin Jr. 2001. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. Journal of Biological Chemistry 276: 18934–18940.
32. Yao, J.E., M. Yan, Z. Guan, C.B. Pan, L.P. Xia, C.X. Li, L.H. Wang, Z.J. Long, Y. Zhao, M.W. Li, F.M. Zheng, J. Xu, D.J. Lin, and Q. Liu. 2009. Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Molecular Cancer 8: 95.
33. Song, J., S. Salek-Ardakani, T. So, and M. Croft. 2007. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nature Immunology 8: 64–73.